

Video Abstracts

Paroxysmal Kinesigenic Dyskinesia

Martin Paucar^{1,2*}, Helena Malmgren^{3,4} & Per Svenningsson^{1,2}

¹Department of Neurology, Karolinska University Hospital Huddinge, Stockholm, Sweden, ²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ³Department of Clinical Genetics, Karolinska University Hospital Solna, Stockholm, Sweden, ⁴Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

Abstract

Background: Paroxysmal kinesigenic dyskinesia (PKD) is a rare condition associated with heterozygous mutations in the proline-rich transmembrane protein 2 (*PRRT2*) gene.

Phenomenology Shown: In this article we illustrate the phenomenology of PKD in a male previously misdiagnosed with Tourette's syndrome.

Educational Value: Regardless of the underlying phenotype, PKD is highly responsive to some antiepileptic drugs.

Keywords: Paroxysmal kinesigenic dyskinesia, *PRRT2*, carbamazepine

Citation: Paucar M, Malmgren H, Svenningsson P. Paroxysmal kinesigenic dyskinesia. *Tremor Other Hyperkinet Mov.* 2017; 7. doi: 10.7916/D8R79N2F

*To whom correspondence should be addressed. E-mail: martin.paucar-arce@sl.se

Editor: Elan D. Louis, Yale University, USA

Received: November 6, 2017 **Accepted:** November 29, 2017 **Published:** December 12, 2017

Copyright: © 2017 Paucar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original authors and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.

Funding: Stockholm County Council.

Financial Disclosures: None.

Conflicts of Interest: The authors report no conflict of interest.

Ethics Statement: This study was performed in accordance with the ethical standards detailed in the Declaration of Helsinki. The authors' institutional ethics committee has approved this study and all patients have provided written informed consent.

A 28-year-old male with paroxysmal and short-lasting dystonia triggered by sudden movement was evaluated at our center. Many short-lasting dystonia events occurred per day; these were preceded by aura-like symptoms (e.g., paresthesias in the affected limb). Consciousness was preserved during these episodes and physical examination between dystonia episodes was normal. Symptom onset in this case was at age 11. Epilepsy was suspected first; however, repeat investigations with electroencephalography and neuroimaging were normal. The patient's presentation was previously misinterpreted as Tourette's syndrome despite the absence of vocal tics. This presentation is rather compatible with paroxysmal kinesigenic dyskinesia (PKD), a rare movement disorder associated in most cases with heterozygous mutations in the proline-rich transmembrane protein 2 (*PRRT2*) gene (*DYT10*).¹ Targeted analysis of this gene (both sequencing and MLPA) was normal and whole-genome sequencing was not contributory in this case. Focal dystonia, in either the toes or the arms, was evident after standing up and running. In addition, running triggered generalized dystonia with falls and impaired speech, which are unusual in PKD (Video 1). Dystonia receded completely after treatment with carbamazepine was initiated. This good treatment response to antiepileptic drugs



Video 1. Phenomenology of Paroxysmal Kinesigenic Dyskinesia in a 28-year-old Male. **Segment 1.** Mild and short-lasting posturing in the left big toe after standing up. Running triggers generalized dystonia leading to a fall and impaired speech; consciousness is preserved. **Segment 2.** This segment shows the remarkable good response to carbamazepine.

(carbamazepine or phenytoin) constitutes one of the criteria proposed for PKD.² Other hyperkinesias that can occur in PKD patients include chorea and/or ballism.^{2,3} Aura-like symptoms (paresthesias and stiffness

in the affected limb) before the attacks, as described in this case, are very common.³ Differential diagnosis of PKD includes several acquired conditions affecting the basal ganglia and familial conditions such as paroxysmal exercise-induced dyskinesia, paroxysmal hypnogenic dyskinesia, and glucose transporter type 1 deficiency syndrome (Glut1-DS).³

References

1. Lee HY, Huang Y, Bruneau N, Roll P, Roberson EDO, Hermann M, et al. Mutations in the gene *PRRT2* cause paroxysmal kinesigenic dyskinesia with infantile convulsions. *Cell Rep* 2012;1:2–12. doi: 10.1016/j.celrep.2011.11.001
2. Bruno MK, Hallett M, Gwinn-Hardy K, Sorensen B, Considine E, Tucker S, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. *Neurology* 2004;63:2280–2287. doi: 10.1212/01.WNL.0000147298.05983.50
3. Spacey S, Adams P. Familial paroxysmal kinesigenic dyskinesia. June 24, 2005 (Updated 2013 Jun 27). In: Pagon RA, Adam MP, Ardinger HH, et al., editors. *GeneReviews*® Seattle (WA): University of Washington, Seattle; 1993–2017. (Accessed September 21 2017). Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1460/>